ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In fact, the maintenance CML LSCs in patients who are resistance to TKI therapy indicates the role of CML LSCs in resistance to therapy through survival mechanisms that are not completely dependent on BCR-ABL activity.